UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design

Clinical pharmacology and therapeutics, 2011-02, Vol.89 (2), p.234-242

2011

Volltextzugriff (PDF)

Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy

Clinical pharmacology and therapeutics, 2008-01, Vol.83 (1), p.172-176

2008

Volltextzugriff (PDF)

Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs

Clinical pharmacology and therapeutics, 2007-01, Vol.81 (1), p.104-107

2007

Volltextzugriff (PDF)

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

Clinical pharmacology and therapeutics, 2009-08, Vol.86 (2), p.175-182

2009

Volltextzugriff (PDF)

Calcitonin gene-related peptide: key regulator of cutaneous immunity

Acta Physiologica, 2015-03, Vol.213 (3), p.586-594

2015

Volltextzugriff (PDF)

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

Annals of oncology, 2014-01, Vol.25 (1), p.236-240

2014

Volltextzugriff (PDF)

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

Clinical pharmacology and therapeutics, 2008-10, Vol.84 (4), p.475-480

2008

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

Clinical pharmacology and therapeutics, 2008-02, Vol.83 (2), p.293-299

2008

Volltextzugriff (PDF)

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Leukemia, 2012-12, Vol.26 (12), p.2554-2557

2012

Volltextzugriff (PDF)

Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development

Clinical pharmacology and therapeutics, 2014-02, Vol.95 (2), p.138-140

2014

Volltextzugriff (PDF)

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

Clinical pharmacology and therapeutics, 2010-12, Vol.88 (6), p.801-808

2010

Volltextzugriff (PDF)

Fluctuating lattice Boltzmann

Europhysics letters, 2005-08, Vol.71 (3), p.473-479

2005

Volltextzugriff (PDF)

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin

Clinical pharmacology and therapeutics, 2007-05, Vol.81 (5), p.761-767

2007

Volltextzugriff (PDF)

Accelerating Biomedical Research Through Open Knowledge Creation and Stewardship

Clinical pharmacology and therapeutics, 2013-06, Vol.93 (6), p.476-478

Wagner, J A

2013

Volltextzugriff (PDF)

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

Clinical pharmacology and therapeutics, 2012-01, Vol.91 (1), p.109-122

2012

Volltextzugriff (PDF)

Can tuberculosis case finding among health-care seeking adults be improved? Observations from Bissau

The international journal of tuberculosis and lung disease, 2014-03, Vol.18 (3), p.277-285

2014

Volltextzugriff (PDF)

Being small for gestational age is not an independent risk factor for mortality in neonates with congenital diaphragmatic hernia: a multicenter study

Journal of perinatology, 2022-09, Vol.42 (9), p.1183-1188

2022

Volltextzugriff (PDF)

Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2582-2588

2013

Volltextzugriff (PDF)

Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Clinical pharmacology and therapeutics, 2015-07, Vol.98 (1), p.12-15

2015

Volltextzugriff (PDF)

Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR

The international journal of tuberculosis and lung disease, 2017-01, Vol.21 (1), p.67-72

2017

Volltextzugriff (PDF)

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study

Clinical pharmacology and therapeutics, 2012-07, Vol.92 (1), p.96-102

2012

Volltextzugriff (PDF)

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

Clinical pharmacology and therapeutics, 2007-06, Vol.81 (6), p.849-857

2007

Volltextzugriff (PDF)

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Clinical pharmacology and therapeutics, 2008-12, Vol.84 (6), p.679-683

2008

Volltextzugriff (PDF)

Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

Clinical pharmacology and therapeutics, 2012-08, Vol.92 (2), p.243-250

2012

Volltextzugriff (PDF)

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

Clinical pharmacology and therapeutics, 2009-07, Vol.86 (1), p.32-43

2009

Volltextzugriff (PDF)

1 – 25 von 53.545

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43.207)
Mit Volltextzugriff
(43.159)

Publikationsform

9 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(29.609)
Life Sciences & Biomedicine
(18.129)
Humans
(12.753)
Physical Sciences
(8.234)
Male
(7.263)
Female
(7.037)
Biological And Medical Sciences
(6.500)
Technology
(6.172)
Animals
(5.879)
Physics
(5.391)
Medical Sciences
(4.342)
Adult
(4.237)
Middle Aged
(3.808)
Exact Sciences And Technology
(2.914)
Aged
(2.671)
Fundamental And Applied Biological Sciences. Psychology
(2.424)
Chemistry
(2.396)
Engineering
(2.096)
Materials Science
(1.979)
Computer Science
(1.946)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(20.021)
EZB Electronic Journals Library
(18.771)
MEDLINE
(18.601)
Journals@Ovid
(12.114)
Publisher website
(11.137)
Elsevier ScienceDirect Journals
(9.976)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(6.909)
Wiley Online Library
(6.096)
IngentaConnect Journals
(5.795)
Springer journals
(5.131)
Wiley Online Library Full Collection 2018
(3.953)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.905)
JSTOR
(2.451)
American Physical Society Journals
(2.126)
Ebook Central Perpetual and DDA
(2.115)
eBooks on EBSCOhost
(2.006)
Oxford journals
(1.987)
IEEE Xplore Digital Library
(1.980)
PROLA (Physical Review Online Archive)
(1.879)
Springer Book Series
(1.441)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design

Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy

Biomarkers and Surrogate End Points for Fit-for-Purpose Development and Regulatory Evaluation of New Drugs

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

Calcitonin gene-related peptide: key regulator of cutaneous immunity

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

Fluctuating lattice Boltzmann

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin

Accelerating Biomedical Research Through Open Knowledge Creation and Stewardship

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

Can tuberculosis case finding among health-care seeking adults be improved? Observations from Bissau

Being small for gestational age is not an independent risk factor for mortality in neonates with congenital diaphragmatic hernia: a multicenter study

Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin

Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

Suchergebnisse filtern